| P/E (FY) | — | Sales (TTM) | NOK 525.4M |
| Earnings (TTM) | -NOK 3.3M | ROE | −0.68% |
| Net Margin | −0.64% | ROIC | 0.00% |
| Debt / Equity | 0.03 | TD / EBITDA | 0.32 |
| EPS Growth 3Y | — | Sales Growth 3Y | 13.37% |
Photocure ASA, with its subsidiaries, researches, develops, produces, markets, and sells pharmaceutical products through Commercial Franchise and Development Portfolio segments. It markets Hexvix/Cysview for detecting and managing bladder cancer and is developing Cevira, a photodynamic drug-device candidate for high-grade cervical dysplasia, under a license with Asieris MediTech, plus a cystoscope agreement with Richard Wolf. Products reach wholesalers, pharmacies, and hospitals across the Nordics, much of Europe, Canada, and the United States. Founded in 1993, it is headquartered in Oslo.
| Market Cap | — | Trading Days | 4105 |
| 52W High | 79.80 |
| 52W Low | 50.50 |
| % Off High | −28.70% |
| YTD | −20.31% | 1Y | −7.93% |
| 3Y | 21.97% | 5Y | −56.56% |
| 10Y | 29.32% | Since incept. (ann.) | 1.27% |
| Ann. Volatility (1Y) | 42.66% | Ann. Volatility (3Y) | 50.43% |
| Sharpe (1Y) | 0.01 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −29.62% | Max Drawdown (3Y) | −32.23% |
| Beta (3Y, vs SPY) | −0.31 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| AMGN | AMGEN INC | $212.16B | 27.6 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| GILD | GILEAD SCIENCES, INC. | $166.77B | 19.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| SYK | STRYKER CORP | $132.87B | 41.3 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| ISRG | INTUITIVE SURGICAL INC | $127.82B | 46.0 |
